Published in Circ Res on October 13, 2011
High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells. Sci Transl Med (2017) 1.44
Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies. J Am Heart Assoc (2014) 1.18
The zebrafish as a tool to identify novel therapies for human cardiovascular disease. Dis Model Mech (2014) 1.03
Zebrafish: A marvel of high-throughput biology for 21(st) century toxicology. Curr Environ Health Rep (2014) 0.97
Interference with ERK(Thr188) phosphorylation impairs pathological but not physiological cardiac hypertrophy. Proc Natl Acad Sci U S A (2013) 0.93
Crosstalk between mitogen-activated protein kinases and mitochondria in cardiac diseases: therapeutic perspectives. Pharmacol Ther (2014) 0.88
Experience with sorafenib in the treatment of advanced renal cell carcinoma. Ther Adv Urol (2012) 0.82
Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity. Pharmacogenomics (2013) 0.82
Physiological, pharmacological and toxicological considerations of drug-induced structural cardiac injury. Br J Pharmacol (2015) 0.81
Inhibition of G-protein-coupled receptor kinase 2 (GRK2) triggers the growth-promoting mitogen-activated protein kinase (MAPK) pathway. J Biol Chem (2013) 0.81
Alterations in cell adhesion proteins and cardiomyopathy. World J Cardiol (2014) 0.80
Up-regulation of hERG K⁺ channels by B-RAF. PLoS One (2014) 0.79
Analysis of Tyrosine Kinase Inhibitor-Mediated Decline in Contractile Force in Rat Engineered Heart Tissue. PLoS One (2016) 0.78
Heart failure-specific changes in protein kinase signalling. Pflugers Arch (2014) 0.78
Advances in the Study of Heart Development and Disease Using Zebrafish. J Cardiovasc Dev Dis (2016) 0.77
Translational Prospects and Challenges in Human Induced Pluripotent Stem Cell Research in Drug Discovery. Cells (2016) 0.76
2-Octadecynoic acid as a dual life stage inhibitor of Plasmodium infections and plasmodial FAS-II enzymes. Bioorg Med Chem Lett (2014) 0.75
Identification of Cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining Pharmacovigilance and Pharmacodynamics. Br J Clin Pharmacol (2017) 0.75
21st Century Cardio-Oncology: Identifying Cardiac Safety Signals in the Era of Personalized Medicine. JACC Basic Transl Sci (2016) 0.75
Kinase inhibitor screening using artificial neural networks and engineered cardiac biowires. Sci Rep (2017) 0.75
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol (2008) 14.74
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res (2003) 9.92
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med (2006) 9.07
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol (2005) 7.12
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet (2007) 6.76
Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2008) 4.50
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist (2007) 3.42
Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol Rev (2010) 2.68
Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun (2007) 2.36
Zebrafish: an emerging model system for human disease and drug discovery. Clin Pharmacol Ther (2007) 1.89
Zebrafish: a preclinical model for drug screening. Assay Drug Dev Technol (2002) 1.70
An alpha1A-adrenergic-extracellular signal-regulated kinase survival signaling pathway in cardiac myocytes. Circulation (2007) 1.64
Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload. Circulation (2004) 1.59
Zebrafish: a new model on the pharmaceutical catwalk. Bioessays (2003) 1.44
Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res (2010) 1.37
An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J Clin Invest (2007) 1.34
Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer (2008) 1.34
Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin Transl Sci (2009) 1.28
Modeling cardiovascular disease in the zebrafish. Trends Cardiovasc Med (2008) 1.19
Fishing for the genetic basis of cardiovascular disease. Dis Model Mech (2009) 1.16
Analysis of the cell cycle in zebrafish embryos. Methods Cell Biol (2004) 1.11
A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother Pharmacol (2010) 1.08
A rapid apoptosis assay measuring relative acridine orange fluorescence in zebrafish embryos. Zebrafish (2007) 1.01
Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies. Leuk Res (2010) 0.92
The zebrafish as a novel tool for cardiovascular drug discovery. Recent Pat Cardiovasc Drug Discov (2009) 0.87
Differences in effects on myocardium and mitochondria by angiogenic inhibitors suggest separate mechanisms of cardiotoxicity. Toxicol Pathol (2010) 0.84
Translational pharmacology in aging men with benign prostatic hyperplasia: molecular and clinical approaches to alpha1-adrenoceptors. Curr Aging Sci (2009) 0.81
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med (2006) 9.07
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet (2007) 6.76
Seven-transmembrane-spanning receptors and heart function. Nature (2002) 5.38
Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest (2005) 4.31
A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med (2008) 3.98
Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology (2008) 3.28
Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation (2002) 3.15
A novel and efficient model of coronary artery ligation and myocardial infarction in the mouse. Circ Res (2010) 3.00
Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys (2010) 2.94
Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol Rev (2010) 2.68
Regulation of beta-adrenergic receptor signaling by S-nitrosylation of G-protein-coupled receptor kinase 2. Cell (2007) 2.65
Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. Nat Med (2007) 2.48
Radiotherapy protocol deviations and clinical outcomes: a meta-analysis of cooperative group clinical trials. J Natl Cancer Inst (2013) 2.35
A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest (2003) 2.32
Animal models of heart failure: a scientific statement from the American Heart Association. Circ Res (2012) 2.31
Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol (2010) 2.30
Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure. Eur Heart J (2005) 2.29
Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res (2003) 2.24
c-Jun N-terminal kinases mediate reactivation of Akt and cardiomyocyte survival after hypoxic injury in vitro and in vivo. Circ Res (2005) 2.23
G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure. Circ Res (2008) 2.22
Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation (2008) 2.17
Hyperphosphorylation of the cardiac ryanodine receptor at serine 2808 is not involved in cardiac dysfunction after myocardial infarction. Circ Res (2012) 2.16
Cyclophilin D controls mitochondrial pore-dependent Ca(2+) exchange, metabolic flexibility, and propensity for heart failure in mice. J Clin Invest (2010) 2.12
Can drugs enhance hypofractionated radiotherapy? A novel method of modeling radiosensitization using in vitro data. Int J Radiat Oncol Biol Phys (2012) 2.12
The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis. Int J Radiat Oncol Biol Phys (2012) 2.10
Differential gene expression and genomic patient stratification following left ventricular assist device support. J Am Coll Cardiol (2003) 2.08
Cardiac-specific ablation of G-protein receptor kinase 2 redefines its roles in heart development and beta-adrenergic signaling. Circ Res (2006) 2.08
Stabilization of beta-catenin by a Wnt-independent mechanism regulates cardiomyocyte growth. Proc Natl Acad Sci U S A (2003) 2.01
A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov (2013) 1.97
COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol (2007) 1.95
Uncovering G protein-coupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes. Proc Natl Acad Sci U S A (2008) 1.93
C1q/tumor necrosis factor-related protein-3, a newly identified adipokine, is a novel antiapoptotic, proangiogenic, and cardioprotective molecule in the ischemic mouse heart. Circulation (2012) 1.90
Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation (2008) 1.84
Negative impact of β-arrestin-1 on post-myocardial infarction heart failure via cardiac and adrenal-dependent neurohormonal mechanisms. Hypertension (2013) 1.83
Gene therapy in heart failure. Circ Res (2008) 1.79
Deletion of GSK-3beta in mice leads to hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation. J Clin Invest (2008) 1.76
Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling. Eur J Cancer (2011) 1.76
Cardioprotective effects of thioredoxin in myocardial ischemia and reperfusion: role of S-nitrosation [corrected]. Proc Natl Acad Sci U S A (2004) 1.76
17beta-estradiol reduces cardiomyocyte apoptosis in vivo and in vitro via activation of phospho-inositide-3 kinase/Akt signaling. Circ Res (2004) 1.74
Differentiation and definition of vascular-targeted therapies. Clin Cancer Res (2005) 1.74
Pharmacological- and gene therapy-based inhibition of protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure. Circulation (2006) 1.73
Biology of intracranial aneurysms: role of inflammation. J Cereb Blood Flow Metab (2012) 1.73
Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue. Circulation (2007) 1.73
Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit. Cancer Cell (2002) 1.71
Improving prognosis of glioblastoma in the 21st century: who has benefited most? Cancer (2011) 1.70
S100A1 genetically targeted therapy reverses dysfunction of human failing cardiomyocytes. J Am Coll Cardiol (2011) 1.68
β-Adrenergic regulation of cardiac progenitor cell death versus survival and proliferation. Circ Res (2012) 1.66
Cardiac S100A1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarction. Circulation (2006) 1.64
Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov (2012) 1.63
Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ Res (2013) 1.62
β-arrestin1-biased β1-adrenergic receptor signaling regulates microRNA processing. Circ Res (2013) 1.59
Cardiac adenoviral S100A1 gene delivery rescues failing myocardium. J Clin Invest (2004) 1.58
Ischemic neoangiogenesis enhanced by beta2-adrenergic receptor overexpression: a novel role for the endothelial adrenergic system. Circ Res (2005) 1.57
Regulation of intracellular pH in human melanoma: potential therapeutic implications. Mol Cancer Ther (2002) 1.57
Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer (2003) 1.56
RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. Int J Radiat Oncol Biol Phys (2012) 1.56
Targeted inhibition of cardiomyocyte Gi signaling enhances susceptibility to apoptotic cell death in response to ischemic stress. Circulation (2008) 1.56
Glycogen-Synthase Kinase3beta/beta-catenin axis promotes angiogenesis through activation of vascular endothelial growth factor signaling in endothelial cells. Circ Res (2005) 1.56
The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments. Cell Cycle (2011) 1.55
Inhibition of cell survival and invasive potential of colorectal carcinoma cells by the tyrosine kinase inhibitor STI571. Cancer Biol Ther (2004) 1.55
Inhibition of the cardiomyocyte-specific kinase TNNI3K limits oxidative stress, injury, and adverse remodeling in the ischemic heart. Sci Transl Med (2013) 1.55
VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int J Radiat Oncol Biol Phys (2007) 1.55
Assessing the value of an optional radiation oncology clinical rotation during the core clerkships in medical school. Int J Radiat Oncol Biol Phys (2012) 1.54
Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model. Sci Transl Med (2011) 1.54
Prognostic factors and outcomes after definitive treatment of female urethral cancer: a population-based analysis. Urology (2012) 1.53
Level of G protein-coupled receptor kinase-2 determines myocardial ischemia/reperfusion injury via pro- and anti-apoptotic mechanisms. Circ Res (2010) 1.52
Cardiac G-protein-coupled receptor kinase 2 ablation induces a novel Ca2+ handling phenotype resistant to adverse alterations and remodeling after myocardial infarction. Circulation (2012) 1.52
Direct evidence of intracrine angiotensin II signaling in neurons. Am J Physiol Cell Physiol (2014) 1.51
Downregulation of adiponectin induced by tumor necrosis factor α is involved in the aggravation of posttraumatic myocardial ischemia/reperfusion injury. Crit Care Med (2011) 1.50
Integrin-linked kinase regulates endothelial cell survival and vascular development. Mol Cell Biol (2004) 1.46
Technique of outpatient placement of intraprostatic fiducial markers before external beam radiotherapy. Urology (2009) 1.45
Effect of percentage of positive prostate biopsy cores on biochemical outcome in low-risk PCa treated with brachytherapy or 3D-CRT. Urology (2009) 1.43
Transgenic overexpression of the Ca2+-binding protein S100A1 in the heart leads to increased in vivo myocardial contractile performance. J Biol Chem (2003) 1.43
The beta-catenin/T-cell factor/lymphocyte enhancer factor signaling pathway is required for normal and stress-induced cardiac hypertrophy. Mol Cell Biol (2006) 1.41
Blockade of NOX2 and STIM1 signaling limits lipopolysaccharide-induced vascular inflammation. J Clin Invest (2013) 1.40
Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2011) 1.40
Suprabasal Dsg2 expression in transgenic mouse skin confers a hyperproliferative and apoptosis-resistant phenotype to keratinocytes. J Cell Sci (2007) 1.39
Vascular-targeted overexpression of G protein-coupled receptor kinase-2 in transgenic mice attenuates beta-adrenergic receptor signaling and increases resting blood pressure. Mol Pharmacol (2002) 1.38
Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res (2010) 1.37
AAV6.βARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model. Eur Heart J (2012) 1.35
CCM3/PDCD10 stabilizes GCKIII proteins to promote Golgi assembly and cell orientation. J Cell Sci (2010) 1.35
Glycogen synthase kinase-3beta regulates post-myocardial infarction remodeling and stress-induced cardiomyocyte proliferation in vivo. Circ Res (2010) 1.33
Glycogen synthase kinase-3beta regulates growth, calcium homeostasis, and diastolic function in the heart. J Biol Chem (2004) 1.33
Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells. J Immunol (2006) 1.33
Reduction of sympathetic activity via adrenal-targeted GRK2 gene deletion attenuates heart failure progression and improves cardiac function after myocardial infarction. J Biol Chem (2010) 1.32
Role of Omi/HtrA2 in apoptotic cell death after myocardial ischemia and reperfusion. Circulation (2004) 1.32
Orai1 and Stim1 regulate normal and hypertrophic growth in cardiomyocytes. J Mol Cell Cardiol (2010) 1.32
Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res (2005) 1.32
Patient-oriented cancer information on the internet: a comparison of wikipedia and a professionally maintained database. J Oncol Pract (2011) 1.31
GRK2 as a novel gene therapy target in heart failure. J Mol Cell Cardiol (2010) 1.31
Calcium influx through Cav1.2 is a proximal signal for pathological cardiomyocyte hypertrophy. J Mol Cell Cardiol (2010) 1.31
Regulated overexpression of the A1-adenosine receptor in mice results in adverse but reversible changes in cardiac morphology and function. Circulation (2006) 1.30
Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res (2003) 1.29
Interaction with LC8 is required for Pak1 nuclear import and is indispensable for zebrafish development. PLoS One (2009) 1.29
Differential myocardial gene expression in the development and rescue of murine heart failure. Physiol Genomics (2003) 1.28
Lymphocyte levels of GRK2 (betaARK1) mirror changes in the LVAD-supported failing human heart: lower GRK2 associated with improved beta-adrenergic signaling after mechanical unloading. J Card Fail (2006) 1.28
Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin Transl Sci (2009) 1.28